Dermavant Sciences: Dermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old

45.4% of subjects receiving VTAMA achieved the primary endpoint of vIGA-ADTM response of clear (0) or almost clear (1) with at least a 2-grade improvement from baseline at Week 8, versus 13.9% on

Related Keywords

,Eli Lilly ,Angela Salerno Robin ,Laurence Watts ,Gewinn Nur ,Roivant Sciences ,Dermavant Sciences Gmb ,Twitter ,Iqvia National Prescription Audit ,Dermavant Sciences Inc ,Linkedin Dermavant Sciences ,Dermavant Sciences ,Prescribing Information ,All Rights ,Prescription Audit ,Vice President ,Media Relations ,Dermavant ,Ciences ,Reports ,Positive ,Topline ,Results ,Rom ,Adoring ,Second ,Topic ,Dermatitis ,Hase ,Trial ,Mtama ,Tapinarof ,Cream ,Adults ,Children ,Young ,Tears ,